Navigation Links
L'Oreal Paris Celebrates Ten Years of Hope and Healing
Date:9/11/2007

provides information

about the disease and offers ways for people to help support the fight

against ovarian cancer.

- A Special Partnership. In September issues, Hearst Magazines will run a

half-page "bookmark" adjacent to a full page Q&A about ovarian cancer

and a photograph of each editor-in-chief of five different Hearst

women's magazines: Good Housekeeping; Harper's BAZAAR; Marie Claire;

O, The Oprah Magazine and Redbook. In an effort to raise awareness,

each magazine will encourage readers to get involved in the fight

against ovarian cancer, which affects over 22,000 new women a year in

the U.S. alone. The bookmarks introduce a "call to action" for readers

to show their support for the cause by purchasing the Color of Hope

bracelet, with net proceeds benefiting OCRF to fund life-saving

research.

- L'Oreal Paris Ovarian Cancer Awareness Week. From September 17th

through September 21st, L'Oreal Paris will sponsor a company-wide

ovarian cancer awareness week dedicated to building awareness,

compassion and commitment among its employees. The week includes a

"Breaking the Silence Breakfast," which educates employees and

important women in their lives about the signs, symptoms and risk

factors of the disease. The company will also host a "Survivor Beauty

Festival" day of pampering at the L'Oreal Paris salon for ovarian

cancer survivors and those currently undergoing treatment. In

addition, employees will be given the opportunity to receive makeovers

by professional makeup artists using the Color of Hope Makeup

Collection.

- Annual Fundraiser. This year's fundraiser, "L'Oreal Paris Presents ...

A Night of Hope," will be held in Los Angeles on November 7th. The

cocktail party and silent auction will unite famous faces
'/>"/>

SOURCE L'Oreal Paris
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Comparison between warfarin and aspirin
2. Clinical Comparisons Between ADHD Drugs Are Less
3. Differences in brain pattern among liars and cheats in comparison to honest people
4. Disney in Trouble? Negative Excitement in Disneyland, Paris
5. Primary Health Care Parishioners of Second Largest HIV Infected Area in US Fail to Offer HIV Tests
6. Bistronomy is Conquering Dining in Paris
7. 45 Day Jail Sentence for Paris Hilton
8. Paris is Out of the Medical Ward and Back in the Slammer
9. Paris Sex Tape Comes Back to Haunt Her in the Slammer
10. Paris medical Condition is a Sexually Transmitted Infection
11. Paris Hilton Turns to the Virgin Mary to Save Her from the Slammer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 1Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 2Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2